Last reviewed · How we verify
Fluticasone/Azelastine nasal spray
Fluticasone/Azelastine combines a corticosteroid that reduces inflammation with an antihistamine that blocks allergic responses in the nasal passages.
Fluticasone/Azelastine combines a corticosteroid that reduces inflammation with an antihistamine that blocks allergic responses in the nasal passages. Used for Allergic rhinitis (seasonal and perennial).
At a glance
| Generic name | Fluticasone/Azelastine nasal spray |
|---|---|
| Also known as | Dymista |
| Sponsor | University of Chicago |
| Drug class | Intranasal corticosteroid/antihistamine combination |
| Target | Glucocorticoid receptor; H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent intranasal corticosteroid that suppresses inflammatory mediators and immune cell activation in nasal tissue. Azelastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Together, they provide dual anti-inflammatory and antihistamine effects for allergic rhinitis management.
Approved indications
- Allergic rhinitis (seasonal and perennial)
Common side effects
- Headache
- Nasal irritation
- Epistaxis
- Dysgeusia (bitter taste)
- Somnolence
Key clinical trials
- INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION (PHASE4)
- Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (PHASE4)
- Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis (PHASE4)
- Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray (PHASE1)
- Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (PHASE2)
- Dymista Allergen Chamber - Onset of Action Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone/Azelastine nasal spray CI brief — competitive landscape report
- Fluticasone/Azelastine nasal spray updates RSS · CI watch RSS
- University of Chicago portfolio CI